Sulopenem

Summary

Sulopenem (CHEMBL1908305) is a phase-3 clinical-stage small molecule; indicated across 4 conditions including urinary tract infection and bacterial pneumonia.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 4 conditions
• Clinical trials: 5
• Chemistry: 349.5 Da · C12H15NO5S3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1908305
Name	Sulopenem
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	9950244
Molecular formula	C12H15NO5S3
Molecular weight	349.5
InChIKey	FLSUCZWOEMTFAQ-PRBGKLEPSA-N

SMILES: C[C@H]([C@@H]1[C@@H]2N(C1=O)C(=C(S2)S[C@H]3CC[S@@](=O)C3)C(=O)O)O

IUPAC name: (5R,6S)-6-[(1R)-1-hydroxyethyl]-7-oxo-3-[(1R,3S)-1-oxothiolan-3-yl]sulfanyl-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid

Also known as: CP-70,429, CP-70429, Sulopenem, sulopenem, SULOPENEM

Patent coverage: 31 distinct patent families (83 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
urinary tract infection	3	MONDO:0100338	EFO:0003103
bacterial pneumonia	2	MONDO:0004652	EFO:1001272
pneumonia	1	MONDO:0005249	EFO:0003106

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
PHASE3	2
PHASE1	2
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03357614	PHASE3	COMPLETED	Sulopenem Followed by Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro for Complicated UTI in Adults
NCT03358576	PHASE3	COMPLETED	Sulopenem Versus Ertapenem for Complicated Intra-abdominal Infection (cIAI)
NCT00797108	PHASE2	COMPLETED	A Study Of Intravenous Sulopenem And Oral PF-03709270 In Community Acquired Pneumonia That Requires Hospitalization
NCT00759564	PHASE1	COMPLETED	A Study To Investigate The Pharmacokinetics, Safety And Tolerability Of An Intravenous And Oral Form Of A Compound In Subjects With Varying Degrees Of Renal Impairment And Normal Renal Function
NCT04700787	PHASE1	WITHDRAWN	Safety, Tolerability, and Pharmacokinetics of Sulopenem in Adolescents

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).